Abstract
There have been no published studies evaluating the efficacy and safety of weekly liposomal amphotericin B as secondary prophylaxis in leukemic patients with invasive fungal infections (IFIs). We found in a retrospective review of our experience with 14 such patients admitted from 2003–2009 that the use of this approach was associated with frequent relapse of IFIs (36%) and kidney injury (36%).
Acknowledgements
This research was supported in part by an educational grant DR10-0174 by Astellas Pharma US. It was also supported in part by the National Institutes of Health through MD Anderson's Cancer Center Support, Grant CA016672.
Declaration of interest: D.P.K. is a member of the speakers’ bureau of and/or has received honoraria from Merck & Co., Inc.; Pfizer; Enzon Pharmaceuticals; and Fujisawa/Astellas Pharma US. He also has been a consultant and member of the advisory board for Merck & Co., Inc., and Schering-Plough. The other authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.
This paper was first published online on Early Online on 21 November 2011.